title: Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients.
abstract: BACKGROUND
  We compared treatment completion rates and safety of docetaxel and cyclophosphamide six- cycle therapy (TC6) with docetaxel followed by 5FU, epirubicin and cyclophosphamide (T-FEC) therapy in Japanese patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
  
  
  METHODS
  We administered TC6 q3w or T-FEC q3w to HER2-negative breast cancer patients. The primary endpoint of this trial was toxicity. As second endpoints, the treatment completion rate and relative dose intensity were evaluated.
  
  
  RESULTS
  The TC6 and T-FEC group consisted of 22 and 21 patients, respectively. Concerning hematological toxicity, grade 3 or higher adverse reactions included neutropenia and febrile neutropenia. As non-hematological adverse events, exanthema and peripheral neuropathy were frequently reported in the TC6 group, whereas more patients of the T-FEC group reported nausea and vomiting. In TC6, the treatment completion rate was 86.4% and the relative dose intensity of docetaxel was 93.2%. In T-FEC, the values were 95.2% and 98.9%, respectively.
  
  
  CONCLUSIONS
  These results suggest that TC6 is tolerable in Japanese, and that this regimen can also be performed in outpatient clinics. However, with the TC6 regimen, the compliance was slightly lower than with the T-FEC regimen, and supportive therapy needs to be managed appropriately.
authors.affiliation: Breast Center, Bell Land General Hospital, Osaka, Japan E-mail : abe@belle.shiga-med.ac.jp.
authors.forename: Hajime
authors.initials: H
authors.lastname: Abe
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Mori
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kawai
authors.forename: Kaori
authors.initials: K
authors.lastname: Tomida
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kubota
authors.forename: Tomoko
authors.initials: T
authors.lastname: Umeda
authors.forename: Tohru
authors.initials: T
authors.lastname: Tani
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D003520:Cyclophosphamide; D000077143:Docetaxel; D015251:Epirubicin; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; C508053:ERBB2 protein, human